Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.29 USD

87.29
1,527,629

-0.38 (-0.43%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $87.32 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

    Here's Why Investors Should Buy Edwards Lifesciences Now

    Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

      Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

      IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

        Is Edwards Lifesciences Corporation (EW) a Great Growth Stock?

        Edwards Lifesciences Corporation (EW) is a company that might be well-positioned for future earnings growth.

          Here's Why Investors Should Buy Align Technology (ALGN) Now

          Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.

            Abbott-North West London Pathology Expand in Diagnostics

            Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

              Intuitive Surgical at 52-Week High: What's Driving the Stock?

              Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.

                Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study

                Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.

                  Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

                  Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.

                    Varian (VAR) Rides on Oncology and Proton Therapy Businesses

                    Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.

                      Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss

                      Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.

                        Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes

                        Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                          STERIS (STE) Banks on Organic Growth, Competition Intense

                          STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.

                            BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife

                            The company achieved annualized supply chain improvement since the acquisition of Home Solutions.

                              OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2

                              OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                                CVS Health Grows on Specialty Pharmacy amid Retail Woes

                                CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.

                                  Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

                                  Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.

                                    Haemonetics Banks on Solid Plasma & Haemonetics Management

                                    Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

                                      Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

                                      Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

                                        Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat

                                        Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.

                                          STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up

                                          STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.

                                            BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

                                            BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

                                              BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates

                                              BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.

                                                Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

                                                Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                                                  Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2

                                                  Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.